

References

L-215

1. The National Center for Biotechnology Information (NCBI). *PALB2* partner and localizer of *BRCA2* [Homo sapiens (human)]. Gene ID: 79728, updated May 28, 2017.
2. Rosenthal ET, Evans B, Kidd J, et al. Increased identification of candidates for high-risk breast cancer screening through expanded genetic testing. *J Am Coll Radiol*. 2017; 14(4):561-568.
3. Kluska A, Balabas A, Piatkowska M, et al. *PALB2* mutations in *BRCA* 1/2-mutation negative breast and ovarian cancer patients from Poland. *BMC Medical Genomics*. 2017; 10:14
4. Afghahi A, Kurian AW. The changing landscape of genetic testing for inherited breast cancer predisposition. *Curr Treat Options Oncol*. 2017; 18(5):27.
5. Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. *Cancer*. 2017; 123:1721-1730.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V2.2017.
7. Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in *BRCA* mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. *Annals of Oncology*. 2016;27(5):v103-v110.
8. Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). *The Breast*. 2016;26:87-99.
9. Antoniou AC, Casadei T, Heikkinen D, et al. Breast-cancer risk in families with mutations in *PALB2*. *The New England Journal of Medicine*. 2014; 371(6): 497-506.
10. Bunnell AE, Garby CA, Pearson EJ, et al. The clinical utility of next generation sequencing results in a community-based hereditary cancer risk program. *J Genet Counsel*. 2017; 26:105-112.
11. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the *BRCA2*-interacting protein *PALB2* to familial breast cancer. *Cancer Res*. Mar 15 2011;71(6):2222-2229.
12. Catucci I, Peterlongo P, Ciceri S, et al. *PALB2* sequencing in Italian familial breast cancer cases reveals a high risk mutation recurrent in the province of Bergamo. *Genet Med*. Sep 2014;16(9):688-694.
13. Couch FJ, Shimelis H, Hu C, et al. Association between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol*. 2017; Apr 13.
14. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a *PALB2* mutation: a prospective cohort analysis. *Lancet Oncol*. 2015;16(6):638-644.
15. Erkkö H, Dowty JG, Nikkila J, et al. Penetrance analysis of the *PALB2* c.1592delT founder mutation. *Clin Cancer Res*. 2008;14(14):4667-4671.
16. Heikkinen T, Karkkainen H, Aaltonen K, et al. The breast cancer susceptibility mutation *PALB2* 1592delT is associated with an aggressive tumor phenotype. *Clin Cancer Res*. May 1 2009;15(9):3214-3222.

17. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. *Systematic Reviews*. 2012; 1:10.
18. Moran O, Kikitina D, Royer, et al. Revisiting breast cancer patients who previously tested negative for *BRCA* mutations using a 12-gene panel. *Breast Cancer Res Treat*. 2017;161:135-142.
19. Rahman N, Seal S, Thompson D, et al. *PALB2*, which encodes a *BRCA2*-interacting protein, is a breast cancer susceptibility gene. *Nat Genet*. 2007;39(2):165-167.
20. Thompson ER, Goringe KL, Rowley SM, et al. Prevalence of *PALB2* mutations in Australian familial breast cancer cases and controls. *Breast Cancer Res*. 2015;17(1):111.